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Nadia Ayala-Lopez*, Janice M. Thompson and Stephanie W. Watts
Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, USA
Background: Perivascular adipose tissue (PVAT) can decrease vascular contraction
to NE. We tested the hypothesis that metabolism and/or uptake of vasoactive amines
by mesenteric PVAT (MPVAT) could affect NE-induced contraction of the mesenteric
resistance arteries.
Methods: Mesenteric resistance vessels (MRV) and MPVAT from male Sprague-Dawley
rats were used. RT-PCR andWestern blots were performed to detect amine metabolizing
enzymes. The Amplex® Red Assay was used to quantify oxidase activity by detecting the
oxidase reaction product H2O2 and the contribution of PVAT on the mesenteric arteries’
contraction to NE was measured by myography.
Results: Semicarbazide sensitive amine oxidase (SSAO) and monoamine oxidase
A (MAO-A) were detected in MRV and MPVAT by Western blot. Addition of the
amine oxidase substrates tyramine or benzylamine (1 mM) resulted in higher amine
oxidase activity in the MRV, MPVAT, MPVAT’s adipocyte fraction (AF), and the stromal
vascular fraction (SVF). Inhibiting SSAO with semicarbazide (1 mM) decreased amine
oxidase activity in the MPVAT and AF. Benzylamine-driven, but not tyramine-driven,
oxidase activity in the MRV was reduced by semicarbazide. By contrast, no reduction
in oxidase activity in all sample types was observed with use of the monoamine oxidase
inhibitors clorgyline (1µM) or pargyline (1µM). Inhibition of MAO-A/B or SSAO individually
did not alter contraction to NE. However, inhibition of both MAO and SSAO increased the
potency of NE at mesenteric arteries with PVAT. Addition of MAO and SSAO inhibitors
along with the H2O2 scavenger catalase reduced PVAT’s anti-contractile effect to NE.
Inhibition of the norepinephrine transporter (NET) with nisoxetine also reduced PVAT’s
anti-contractile effect to NE.
Conclusions: PVAT’s uptake and metabolism of NE may contribute to the
anti-contractile effect of PVAT. MPVAT and adipocytes within MPVAT are a source of
SSAO.
Keywords: norepinephrine, monoamine oxidase, semicarbazide sensitive amine oxidase, amine oxidase (copper-
containing), isometric contraction, uptake transporters, norepinephrine transporter, organic cation transporter
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INTRODUCTION
Perivascular adipose tissue (PVAT) makes up the fourth layer of
most blood vessels (Chaldakov et al., 2007). PVAT is appreciated
for its effects on the vasculature, from mediating relaxation
(Brandes, 2007; Fesus et al., 2007) to stimulating contraction
of arteries by the release of catecholamines (Gao et al., 2006;
Ayala-Lopez et al., 2014). Increased visceral fat, which includes
mesenteric fat, is associated with increased cardiovascular
risk (Kotchen, 2010). Thus, our focus is on the mesenteric
PVAT because it surrounds resistance arteries, which provide
increased vascular resistance in hypertension (for a review:
Intengan and Schiffrin, 2000). Investigating mesenteric PVAT’s
mechanisms of handling NE, the sympathetic neurotransmitter,
is relevant in understand the pathology in this disease because
sympathetic nervous system activity is increased in obesity-
related hypertension (Hall et al., 2010).
In normal (non-disease) animal models, PVAT inhibits
contraction of the underlying arteries to several agonists,
including norepinephrine (NE) (Soltis and Cassis, 1991; Löhn
et al., 2002) in a mechanism dependent on transport-dependent
uptake of NE. Mesenteric and aortic PVAT can take up NE
applied exogenously, which could contribute to PVAT’s anti-
contractile effect on mesenteric and aortic arteries exposed
to NE (Ayala-Lopez et al., 2015). Nerve terminals terminate
NE activation of post-synaptic receptors through uptake of
NE followed by storage into vesicles and/or by degradation
by NE metabolizing enzymes. Like nerves, PVAT also has a
storage of catecholamines (Ayala-Lopez et al., 2014) but whether
degradation of NE occurs within PVAT has not been investigated.
PVAT affects arterial contraction through an adrenergic
system that is complete with the release and uptake of NE
(Ayala-Lopez et al., 2014, 2015). We hypothesize that PVAT’s
anti-contractile effect is through its amine metabolizing activity
in addition to NE uptake. The NE metabolizing enzymes
monoamine oxidases A (MAO-A) and monoamine oxidase B
(MAO-B) are present in human white adipose tissue adipocytes
isolated from mammary and abdominal lipectomies (Pizzinat
et al., 1999). One study supports the presence in adipose
tissue (canine subcutaneous) of catechol-o-methyl transferase
(COMT), another metabolizer of NE (Belfrage et al., 1977).
Lastly, the dual function enzyme, semicarbazide sensitive amine
oxidase (SSAO), also known as vascular adhesion protein-1
(VAP-1) for its role as a leukocyte adhesion molecule, catalyzes
the deamination of amines. SSAO is shed from the plasma
membrane of adipocytes. Circulating levels of SSAO are elevated
in cardiovascular disease (Abella et al., 2004) and atherosclerosis
(Karadi et al., 2002) making SSAO in PVAT an interesting target
of study. NE is a substrate for SSAO in rat brown adipose tissue
(Barrand and Callingham, 1982). The presence of and the effect
Abbreviations: 5-HT, 5-hydroxytryptamine; AF, adipocyte fraction; COMT,
catechol-o-methyl-transferase; DMSO, dimethyl sulfoxide; MAO, monoamine
oxidase; MPVAT, mesenteric perivascular adipose tissue; MRV, mesenteric
resistance vessels; NE, norepinephrine; NET, norepinephrine transporter; OCT3,
organic cation transporter 3; PVAT, perivascular adipose tissue; SVF, stromal
vascular fraction; SSAO, semicarbazide sensitive amine oxidase; WAT, white
adipose tissue.
that amine metabolism in PVAT on vascular contraction to NE is
not known.
To study NE handling in PVAT, we used mesenteric
resistance arteries with and without PVAT. Additionally, PVAT
was separated into its fractional components, the adipocyte
fraction (AF) and the stromal vascular fraction (SVF). The
stromal vascular fraction is the non-buoyant fraction separated
from PVAT. It contains fibroblasts, mesenchymal stem cells,
lymphocytes, macrophages and endothelial cells (Szasz et al.,
2013). Gene expression analysis and Western blots helped
to identify which NE metabolizing enzymes are present in
mesenteric resistance vessels (MRV- pooledmesenteric resistance
arteries and veins) and in their surrounding MPVAT. We
measured oxidase activity after the addition of tyramine or
benzylamine, substrates of MAO and SSAO (Visentin et al.,
2005) and used pharmacological inhibitors of amine oxidases
to determine which oxidases are important for the activity
observed. Contraction to NEwas recorded in isolated third-order
mesenteric arteries with and without PVAT exposed to inhibitors
of MAO-A/B, SSAO and NE transporters. Our work presents
insight into the impact of PVAT on arterial contraction to NE.
MATERIALS AND METHODS
Chemicals
Norepinephrine hydrochloride, nisoxetine hydrochloride,
semicarbazide hydrochloride, and catalase were purchased
from Sigma-Aldrich (St. Louis, MO). Pargyline hydrochloride
for the contractility experiments was purchased from Cayman
Chemical (Ann Arbor, MI). Corticosterone was purchased from
Tocris Bioscience (United Kingdom). Pargyline and clorgyline
used in the oxidase assay experiments were supplied within the
Amplex R© Red Monoamine Oxidase Assay Kit (cat# A12214,
ThermoFisher Scientific, Grand Island, NY USA).
Animals
Male Sprague-Dawley rats (225–275 g or ∼8–10 weeks of age,
Charles River, Indianapolis, IN USA) were used. All protocols
were approved by the MSU Institutional Animal Care and Use
Committee and follow the “Guide for the Care and Use of
Laboratory Animals,” 8th edition, 2011. Rats were anesthetized
with sodium pentobarbital (60–80 mg/kg, IP). Anesthesia was
verified by lack of paw pinch and eye blink reflexes. Death was
assured by pneumothorax and exsanguination after which tissues
were removed for one of the following protocols.
Tissue Dissection
The liver was collected, snap frozen in liquid N2 and saved to
serve as a positive control for the RT-PCR and Western blot
assays. Mesentery, brain and aorta were collected in physiological
salt solution (PSS); in mM; 130 NaCl; 4.7 KCl; 1.18 KH2PO4;
1.17 MgSO4 7H2O; 14.8 NaHCO3; 5.5 dextrose; 0.03 CaNa2
ethylenediaminetetraacetic acid; 1.6 CaCl2 (pH 7.2). A portion
the rat brain corresponding to the midbrain and pons was
dissected and the aorta was cleaned of PVAT. Both samples
were then saved in potassium phosphate buffer (50 mM) for the
oxidase activity assay. The same tissues (brain and aorta without
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PVAT) from a separate set of animals were dissected, frozen in
liquid N2 and saved for RT-PCR. MPVAT and the associated
mesenteric resistance arteries and veins (MRV) were separated
out in a Sylgard R© coated petri dish in PSS with the aid of a
stereomicroscope. The MPVAT was either used for fractionation,
frozen in liquid N2 for protein isolation, or saved in potassium
phosphate buffer (50 mM) for the oxidase assay. The MRV were
either frozen in liquid N2 for protein or RNA isolation, or saved
in potassium phosphate buffer (50 mM). Samples for the oxidase
activity assays were saved at −20◦C and used within 1 week.
Mesenteric resistance arteries (2 mm in length) with or without
PVAT for the use in isometric contraction experiments were
dissected out in a Sylgard R© coated petri dish in PSS with the aid
of a stereomicroscope.
Adipocyte and SVF Isolation
MPVAT was added to 1 mL of PSS with 1 mg/mL collagenase
from Clostridium histolyticum type IA (cat# C9891, Sigma) and
incubated at 37◦C with gentle agitation until fully digested.
The sample was centrifuged at 200 × g for 5 min after which
the SVF was transferred into a separate tube. The fractions
were then washed six times by adding 1 mL of PSS and
centrifuging at 200 × g for 10 min. This protocol is one used to
routinely isolate adipocytes and that has been verified by other
groups to satisfactorily exclude other cell types (Vargovic et al.,
2013). Purity of the isolation (>95% adipocytes) was verified
by counting the adipocytes vs. non-adipocytes present with a
hemocytometer. Phase contrast images of the fractions were
taken with a 20× objective (Hi PLAN I 20X/ 0.30 PH1) on an
inverted microscope DMi1 (Leica, Buffalo Grove, IL, USA) using
Leica Application Suite (LAS). The PSS was then removed and
the samples were placed in 50 mM potassium phosphate buffer
to be used in the oxidase assay before freezing or snap frozen in
liquid N2 for protein isolation.
Real-Time PCR
All tissues (brain, liver, MRV, MPVAT, and aorta) were
homogenized using the Bead Ruptor 24 (Omni International,
NW Kennesaw, GA). RNA was extracted with the Quick
RNA MiniPrep kit (cat# R1054, Zymo Research Corporation,
Irving, CA USA) and purity (260/280 and 260/230 ratios ≥
1.8) was verified using a Nanodrop 2000C spectrophotometer
(Thermo Scientific, Wilmington, DE USA). The mRNA (1
µg) was reverse transcribed with the High-Capacity cDNA
Reverse Transcription Kit (cat# 4368814, ThermoFisher
Scientific). RT-PCR was performed using PerfeCTa FastMix
II, ROX (cat# 95119, Quanta Biosciences, Gaithersburg,
MD USA) on the ABI 7500 Fast Real Time PCR system
(Life Technologies, Carlsbad, CA USA) with the following
parameters: 95◦C for 20 s, 95◦C for 1 s and 60◦C for 20 s for
40 cycles. Taqman Primers were purchased from ThermoFisher
Scientific. The sequences are proprietary. Thus, we have listed
the catalog numbers which are as follows: Aoc3 (cat# 4448892,
assay ID: Rn01452826_m1), Comt (cat#4448892, assay ID:
Rn01404927_g1: Actb (cat#4448892, assay ID: Rn00667869_m1),
Maoa (cat#4448892, assay ID: Rn01430950_m1), Maob
(cat#4448892, assay ID: Rn00566203_m1). Measures were
FIGURE 1 | Maoa and Aoc3 are highly expressed in rat mesenteric
PVAT. Amine oxidase gene expression of (A) Maoa, (B) Maob, and (C) Aoc3
(gene for SSAO) in mesenteric resistance vessels (MRV) and in mesenteric
PVAT (MPVAT) normalized to β-actin as the reference gene. Bars represent
means ± SEM. Means were compared with a one-way ANOVA followed by
the Holm-Sidak’s multiple comparisons test for parametric data sets (Maob) or
the Kruskal-Wallis followed by the Dunn’s test for multiple comparisons for the
non-parametric data sets (Maoa and Aoc3). *p < 0.05, **p < 0.01, ****p <
0.0001. The number above each bar indicates the number of animals used.
normalized to β-actin (Actb) and expressed as fold change
relative to the positive control tissue as described by Livak and
Schmittgen (2001).
Western Blots
MPVAT and MRV protein was isolated in phosphate
buffered saline (PBS) with protease inhibitors [sodium
orthovanadate (1 mM), aprotinin/leupeptin (100 µg/ml)
and phenylmethylsulfonyl fluoride (1 mM)] and homogenized
using the Bead Ruptor 24 (Omni International). The protein
from the positive controls was isolated as follows. Stomach
fundus and gut mucosa were dissected from the rat and were
placed into RIPA buffer (cat# R3792, Teknova, Hollister, CA)
with the above protease inhibitors before homogenizing with the
Bead Ruptor 24 (Omni International) and centrifuging at 10,000
rpm for 10 min. Protein from the aorta was isolated in 1X lysis
buffer [Tris HCl (62.5 mM) pH 7.8, 2% SDS, 10% glycerol] with
the above protease inhibitors, frozen in liquid N2, homogenized
with mortar and pestle followed by a centrifugation at 11,000
rpm for 10 min. Supernatants were then separated. The Jurkat
whole cell lysate was purchased from Santa Cruz Biotechnology
(cat# SC-2204, Dallas, TX). The protein concentrations were
determined using the Bicinchoninic Acid Protein Assay Kit
(cat# BCA1, Sigma-Aldrich). The protein samples (50 µg) were
separated on 10% SDS polyacrylamide gels using the Bio-Rad
Mini Protean 3 system. Protein was transferred to PVDF-FL
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FIGURE 2 | MAO-A, MAO-B, and SSAO but not COMT are present in rat MRV and MPVAT. (A) Western blot analysis of monoamine metabolism enzymes
MAO-A, MAO-B, COMT, and SSAO in mesenteric resistance vessels (MRV) and in mesenteric PVAT (MPVAT) from eight animals. Positive controls were gut mucosa
for MAO-A, stomach fundus for MAO-B, Jurkat cells for COMT and aorta for SSAO. Densitometry analysis of Western blot bands for (B) MAO-A, (C) MAO-B,
(D) SSAO. Bars represent the means ± SEM. Western blot densitometry was statistically analyzed with a paired Student’s t-test. *p < 0.05, **p < 0.01.
FIGURE 3 | Tyramine drives amine oxidase activity in the MRV, MPVAT, AF, and SVF. Tyramine, a substrate for amine oxidases, increased the oxidase activity in
the mesenteric resistance vessels (MRV), mesenteric PVAT (MPVAT), adipocyte fraction (AF), and the stromal-vascular fraction (SVF). The brain and aorta were also
tested as positive controls. Bars represent the means ± SEM for the number of animals indicated above each bar. Means were compared by a Mann-Whitney test.
**p < 0.01, ***p < 0.001, ****p < 0.0001 vs. control of that same sample type.
(MAO-A) or nitrocellulose (MAO-B, COMT, VAP-1) and
blocked for 3 h at 4◦C in 4% chicken egg ovalbumin (MAO-A,
β-actin), LI-COR Odyssey Blocking Buffer (MAO-B, COMT) or
5% bovine serum albumin (VAP-1). Primary antibody [MAO-A,
1:200 (epitope corresponds to amino acids 458–527 ofMAO-A of
human origin; Santa Cruz Biotechnology, cat#SC-20156); MAO-
B, 1:200 (epitope near the C-terminus of MAO-B of human
origin; Santa Cruz Biotechnology, cat#SC-18401); COMT, 1:200
(epitope corresponding to amino acids 1-271 of COMT of
human origin; Santa Cruz Biotechnology, cat#SC-25844); VAP1,
1:200 (epitope near the C-terminus of VAP-1 of human origin;
Santa Cruz Biotechnology, cat#SC-13741); or β-actin, 1:2000
(Sigma, cat#A3854)] was incubated overnight in blocking buffer
at 4◦C. Antibody was recovered and blots were washed with TBS
+ 0.1% Tween 20 (TBS-T) for 10 min at 4◦C (three times). Blots
were then incubated with species-specific LI-COR IRDye 800
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FIGURE 4 | SSAO mediates tyramine-driven amine oxidase activity in the MPVAT and its fractions, the AF and SVF, but not the MRV. Percent inhibition of
tyramine driven oxidase activity by pharmacological inhibitors of MAO-A (1 µM clorgyline), MAO-B (1 µM pargyline), both MAO-A and MAO-B (10 µM pargyline) or
SSAO (1 mM semicarbazide) in the (A) mesenteric resistance vessels (MRV), (B) mesenteric PVAT (MPVAT), (C) adipocyte fraction (AF), (D) stromal vascular fraction
(SVF), and the positive controls (E) brain (positive control for MAO-A/B), and (F) aorta (positive control for SSAO). Bars represent the means ± SEM for the number of
animals indicated near each bar. Means were analyzed by a Kruskal-Wallis test followed by the Dunn’s test for multiple comparisons. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001 vs. vehicle control (no inhibition).
secondary antibody (1:1000, MAO-A, MAO-B, COMT, VAP1)
or LI-COR IRDye 700 secondary antibody (1:1000, β-actin) in
LI-COR Odyssey Blocking Buffer for 1 h at 4◦C, followed by
washes with TBS-T for 10 min at 4◦C (three times). Experiments
using a competing peptide (MAO-B: cat#SC-18401 P, VAP-1:
SC-13741 P, Santa Cruz Biotechnology) were performed as above
except for that before the primary antibody was added to the blot
it was incubated overnight at 4◦C with the competing peptide
at 5x the concentration of the antibody. Bands were visualized
using the LI-COR Odyssey Classic or the LI-COR Odyssey CLx.
Densitometry was completed with Image J.
Oxidase Activity Assay
Samples were homogenized with the Bead Ruptor 24 (Omni
International). The samples were centrifuged at 600 × g for
10 min and the supernatant transferred to new tubes. The
protein concentration of an aliquot of the sample was measured
before the oxidase assay using a Bicinchoninic Acid Protein
Assay Kit (cat# BCA1, Sigma-Aldrich) to inform us on the
volume of the sample to load into the assay. MPVAT and the
adipocyte fraction (AF) samples were loaded into a black clear-
bottom 96-well plate at 20mg of protein per well. Twice this
protein, 40 mg, was loaded for the MRV, the SVF, brain (positive
control for MAO) and aorta (positive control for SSAO). More
protein was used for non-adipocyte containing tissues because
the baseline H2O2 production in these extracts was less. Thus,
more was loaded to ensure H2O2 would be detected. Samples
in 1X reaction buffer were added into each well of a 96-well
plate with an inhibitor of metabolism/or vehicle. The plate was
incubated at room temperature for 30 min. Then, the substrate
was added (either tyramine or benzylamine; 1 mM), with 100
µL of the Amplex R© Red Reagent to start the reaction. The plate
was incubated for another 30 min at room temperature after
which the fluorescence was read at 530–560 nm excitation and
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FIGURE 5 | Benzylamine drives amine oxidase activity in MRV, MPVAT, AF, and the SVF. MPVAT, mesenteric PVAT; AF, adipocyte fraction; MRV, mesenteric
resistance vessels; SVF, stromal vascular fraction. The brain and aorta were also tested as positive controls. Bars represent the means ± SEM for the number of
animals indicated above each bar. Means were compared by a two-way ANOVA followed by a Mann-Whitney or a t-test. *p < 0.05, **p < 0.01, ***p < 0.001 vs.
control of that same sample type.
590 nm emission on the Infinite M1000 PRO (Tecan Group
Ltd, Männedorf, Switzerland). Measures were compared to a
resorufin standard curve and expressed as pmol/min/mg of
protein.
Isometric Contraction
Rat third-order mesenteric resistance arteries cleaned of fat
(−PVAT) or with fat intact (+PVAT) were mounted into a
Multi Wire Myograph System 620M (Danish Myo Technology,
Denmark). Data were acquired using a PowerLab Data
Acquisitions unit (ADInstruments, Colorado Springs, CO, USA).
Baths contained warmed, oxygenated PSS. Rings were pulled to
optimum resting tension (13.3 kpa) with the aid of the DMT
Normalization Module for LabChart software and PowerLab
(Danish Myo Technology and ADInstruments; http://cdn.
adinstruments.com/adi-web/brochures/DMT-Normalization-
2011.pdf) and equilibrated for 1 h with washes every 20 min.
The arteries were exposed to an initial concentration of 60 mM
KCl to test viability. Tissues were washed and tone returned to
baseline and exposed to another concentration of 60 mM KCl
to elicit the maximum contraction. The 60 mM KCl maximum
contraction was what we normalized the force of contraction
to. Tissues were then washed and returned to baseline. Either
vehicle or inhibitor was added for 1 h without washing. NE
was then added in a cumulative fashion, with significant time
necessary for a response to plateau prior to the next addition. If
no response was recorded within 3 min, the next concentration
of NE was applied. Tissues were washed and a final 60 mM KCl
addition was performed to test for tissue viability at the end
of the experiment. Data were expressed as percent maximum
contraction. The final contraction to 60 mM KCl was compared
to the initial contraction (Data Supplementary Figures 4, 5). If
the tissue did not contract to the final concentration of 60 mM
KCl, the data for that experiment was not used.
Statistical Analysis
Data are reported as means ± SEM for number of animals
indicated by N or near each bar within the graphs. Statistical
analyses were performed with GraphPad Prism 6.0 (GraphPad
Software, Inc., La Jolla, CA). Outliers were identified and
removed following a Grubb’s test. Contraction was reported as
means ± SEM as a percentage of the initial contraction to 60
mM KCl. Potency means (−logEC50, M) were calculated using
GraphPad Prism 6.0. Where a maximum was not achieved,
the values are estimated and true potencies equal or greater
than that reported. P < 0.05 was considered statistically
significant.
RESULTS
Aoc3 (the gene for SSAO) and Maoa (the
gene for MAO-A) Are Highly Expressed in
MPVAT
MPVAT and the underlying artery-vein pair
(Data Supplementary Figure 1) were dissected from male
Sprague-Dawley rats and analyzed for the expression of amine
metabolizing enzyme genes. Relative Maoa expression in the
MPVAT was similar to that in the brain (Figure 1A), the positive
control for Maoa and Maob (Jahng et al., 1997). However,
MRV expression of Maoa was significantly lower than in the
brain but not the MPVAT. Maob expression was significantly
lower in both the MRV and in the MPVAT vs. the brain
positive control (Figure 1B). When compared to the liver, a
positive control for Comt expression (Karhunen et al., 1994),
MRV and MPVAT had low levels of Comt expression (less
than 0.01-relative expression from liver for both; data not
shown). By contrast, Aoc3 (amine oxidase, copper containing
3; the gene for SSAO) was expressed at higher levels in the
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FIGURE 6 | SSAO mediates benzylamine-driven amine oxidase activity in the MRV, MPVAT and its fractions, the AF and SVF. Percent inhibition of
benzylamine driven oxidase activity by pharmacological inhibitors of MAO-B (1 µM pargyline), both MAO-A and MAO-B (10 µM pargyline) or SSAO (1 mM
semicarbazide) in the (A) mesenteric resistance vessels (MRV), (B) mesenteric PVAT (MPVAT), (C) adipocyte fraction (AF), (D) stromal vascular fraction (SVF), and the
positive controls (E) brain (positive control for MAO-A/B), and (F) aorta (positive control for SSAO). Bars represent the means ± SEM for the number of animals
indicated above each bar. Means were analyzed by a Kruskal-Wallis test followed by the Dunn’s test for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 vs. vehicle control (no inhibition).
MPVAT (Figure 1C) vs. the MRV when compared relative to
the aorta, a positive control for Aoc3 expression (Wanecq et al.,
2006).
MAO-A and SSAO Protein Is Present in
MRV and MPVAT
Western blot analysis of protein isolated from the MRV
and associated MPVAT, revealed presence of MAO-A, MAO-
B and SSAO (Figure 2A). Consistent with there being no
difference between the mRNA expression for Maoa in the
MRV and MPVAT, there was no statistical difference in relative
protein signal between the MRV and MPVAT (p = 0.29;
Figures 2A,B). MAO-B signal was lower the MPVAT than in
the MRV (Figures 2A,C). Bands for COMT were not detected
in either the MRV or the MPVAT (Figure 2A; densitometry not
shown). SSAO signal was higher in the MPVAT vs. the MRV
(Figures 2A,D), also consistent with Figure 1C.
SSAO Mediates Tyramine and
Benzylamine-Induced Amine Oxidase
Activity in MPVAT
Oxidation of amines in the MRV and in the MPVAT could alter
vascular tone through the removal of vasoactive amines and
through the release of the reaction product H2O2. To quantify
the oxidase activity in these tissues, the MRV and MPVAT
were carefully separated. MPVAT was split into its constituent
fractions, the AF and the SVF. A microscopic image of the
separated fractions is shown in Data Supplementary Figure 2,
which represents the AF and SVF used in this study. Tyramine,
a substrate for MAO-A, MAO-B and SSAO, was added to the
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sample extracts to drive oxidase activity. Addition of tyramine
increased the oxidase activity (H2O2 produced) in the MRV,
MPVAT, the AF, and the SVF vs. vehicle (H2O) (Figure 3). The
brain contains bothMAO-A and B activity but low SSAO activity
(Kalaria et al., 1988; Castillo et al., 1999). Thus, the brain served
as a positive control for the MAOs. The brain had higher oxidase
activity in response to tyramine vs. vehicle. The aorta, the positive
control for SSAO, also had higher activity to tyramine vs. vehicle.
To determine which amine oxidase(s) contributed to the
tyramine-driven H2O2 production in the mesentery, the MRV,
MPVAT, AF and the SVF were incubated with inhibitors to each
of the amine oxidases (MAO-A, MAO-B, and SSAO) before
adding tyramine. Clorgyline, an irreversible inhibitor of MAO-
A, was used due to its specificity to MAO-A (IC50 of 0.03
µM and 8 µM at MAO-B (Ozaita et al., 1997) and its lack
of inhibition of SSAO (Clarke et al., 1982). Pargyline (1 µM)
was used to specifically inhibit MAO-B (Ki 0.5 µM) and a
higher concentration (10 µM) was used to inhibit both MAO-
A and B (Ki for pargyline at MAO-A = 15 µM Fowler et al.,
1982). Semicarbazide was used to specifically inhibit SSAO, at
a concentration (1 mM) routinely used in monoamine assays
to selectively inhibit SSAO activity (Ki 15 µM Lizcano et al.,
1996; Repessé et al., 2015). Oxidase activity was quantified as the
amount of H2O2 produced per minute normalized to the amount
of protein.
Tyramine-driven oxidase activity in theMRVwas not reduced
by the addition of clorgyline or pargyline (Figure 4A). However,
there was a non-statistically significant reduction with 1 mM
semicarbazide (Figure 4A). On the other hand, semicarbazide
significantly reduced (almost by 100%) the tyramine-driven
oxidase activity in the MPVAT and the AF (Figures 4B,C).
Oxidase activity in the SVF was not significantly
reduced by inhibition of the MAOs or SSAO vs. vehicle
(Figure 4D). However, each inhibitor (clorgyline, pargyline,
and semicarbazide) caused large non-significant reductions in
oxidase activity. No one enzyme had activity that was higher over
the other enzymes. Thus, each amine oxidase (MAO-A, MAO-B,
and SSAO) may contribute to oxidase activity in the SVF. The
brain had reduced oxidase activity to clorgyline (1 µM- specific
for MAO-A), pargyline (1 µM- specific for MAO and 10 µM-
inhibits both MAO-A and MAO-B), but no reduction with the
SSAO inhibitor semicarbazide (Figure 4E). Oxidase activity in
the aorta was abolished by semicarbazide (1mM); by contrast,
there was not reduction in oxidase activity by clorgyline (1µM)
or pargyline (1µM) (Figure 4F). The results for these controls
support that the assay can detect and distinguish between SSAO
and MAO activity.
Benzylamine differs from tyramine in that it is a substrate
for MAO-B and SSAO only (and not MAO-A). Addition
of benzylamine increased oxidase activity vs. vehicle in the
MPVAT, AF, SVF, brain, and aorta (Figure 5). Amine oxidase
activity in the MRV was abolished by the SSAO inhibitor,
semicarbazide, and was reduced in the MPVAT, AF, and the
SVF (Figures 6A–D). This is different from what was observed
with tyramine as the substrate, where the reduction with
semicarbazide was not significant. Tyramine is a poor substrate
for SSAO compared to benzylamine with a Km of 17.6 mM.
Whereas, the Km of benzylamine for SSAO is 161 µM (Precious
and Lyles, 1988). Some of the tyramine-driven oxidase activity in
the MRV could have been due to other amine oxidases other than
SSAO. Oxidase activity in the brain was completely abolished
by inhibition of MAO-B with pargyline, but was not affected
by inhibition of SSAO (Figure 6E). Oxidase activity in the aorta
was not affected by pargyline, but was reduced significantly by
semicarbazide (Figure 6F).
NE Metabolism Contributes to the
Anti-Contractile Effect of PVAT
Third-order mesenteric resistance arteries with (+) or without
(−) PVAT were mounted on a 4-channel wire myograph.
The force of contraction to 60mM KCl of the arteries with
and without PVAT were not different (Data Supplementary
Figure 3). The arteries were incubated with either vehicle or an
inhibitor prior to the generation of a NE concentration-response
curve. The presence of PVAT gave a significant right-shift of
the NE-response curve (Figure 7). NE had a −logEC50 [M] of
5.64 ± 0.05 in mesenteric resistance—PVAT and a −logEC50
[M] of 5.08 ± 0.06 in arteries +PVAT (Figure 7). Inhibition of
MAO-A and B by 10 µM pargyline, or SSAO by semicarbazide
(1 mM) did not shift the NE concentration-response curve of
arteries+ or−PVAT vs. vehicle (Figures 8A,B). However, a left-
shift of the +PVAT curve was observed with incubation with
semicarbazide + pargyline (10 µM; SP) suggesting that multiple
NE metabolizers may contribute to PVAT’s anti-contractile
effect on mesenteric resistance arteries to NE (Figure 8C). To
understand whether the shift in the NE-curve with SP was due
to H2O2 being produced, we incubated +PVAT arteries with
vehicle, SP, catalase (2000 U/ml), or SP + catalase (2000 U/ml)
for 1 h prior to the addition of NE. The arteries that were
incubated with SP and catalase had a left-shift in their response-
curve to NE vs. those incubated with catalase only (Figure 8D).
FIGURE 7 | PVAT exhibits an anti-contractile effect on mesenteric
arteries exposed to NE. NE-induced contraction of the rat mesenteric
resistance arteries with or without PVAT and with vehicle (no inhibitors present).
Bars represent means ± SEM. N = the number of animals used in each group.
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FIGURE 8 | Metabolism of NE and H2O2 release by PVAT inhibits contraction of rat mesenteric resistance arteries. NE-induced contraction of the rat
mesenteric resistance arteries with or without PVAT and with or without (vehicle) the following inhibitors of NE metabolism. (A) pargyline (10 µM; inhibits MAO-A and
B), (B) semicarbazide (1 mM; inhibits SSAO), (C) SP = semicarbazide (1 mM) and pargyline (10 µM inhibits both MAO-A/B and SSAO). Arteries +PVAT were
incubated with (D) SP and/or catalase (2000 U/ml). Force of contraction was normalized to the percent of the 60 mM KCl contraction. Bars represent means ± SEM.
N = the number of animals used in each group.
However, no shift was observed in the arteries that were exposed
to SP vs. vehicle suggesting that inhibition of metabolism alone
is not always sufficient to affect arterial response to NE and that
both PVAT’s metabolism of NE and production of H2O2 are
involved in decreasing contraction to NE. The pharmacological
parameters for Figures 8B–D are listed in Table 1.
NE Uptake Contributes to the
Anti-Contractile Effect of PVAT
Arteries incubated with the organic cation transporter 3 (OCT3)
inhibitor corticosterone (100 µM), had NE-response curves
(+ and −PVAT) shifted to the left from vehicle (Figure 9A).
However, the −logEC50 of the two curves were not statistically
different (Table 1). Nisoxetine (1 µM), an inhibitor of the
norepinephrine transporter (NET), shifted the NE-curve of
+PVAT arteries significantly to the left vs. vehicle (Figure 9B;
Table 1). We then tested whether transport of NE potentiated
metabolism of NE in PVAT. Inhibition of SSAO [semicarbazide
(1 mM)], MAO-A and B [pargyline (10 µM)], and OCT3
[corticosterone (100 µM); SPC] did not alter PVAT’s anti-
contractile effect when compared to vehicle (Figure 9C). The
curve for the arteries +PVAT incubated with inhibitors was
shifted slightly to the left from arteries +PVAT with vehicle but
this shift was not significant (Table 1). It appears that inhibiting
the entry of NE through OCT3 does not decrease NE removal.
By contrast, inhibition of metabolism and uptake through NET
by SPN [SPN = semicarbazide (1 mM), pargyline (10 µM),
and nisoxetine (1 µM)] shifted the +PVAT curve to the left
(Figure 9D) reflected by an increase in potency of NE on+PVAT
arteries (Table 1).
DISCUSSION
PVAT contains releasable catecholamines and a system for uptake
of NE (Ayala-Lopez et al., 2014, 2015). However, a mechanism
for metabolism for amines in PVAT has not been investigated.
This study demonstrates that the amine oxidase SSAO is present
and highly active in rat MPVAT and MPVAT adipocytes. We
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TABLE 1 | Pharmacological parameters of isolated mesenteric resistance
arteries with (+) or without (−) PVAT.
PVAT Inhibitor −LogEC50 (M) Max Contraction
%60 mM KCl
− Vehicle 5.74 ± 0.11 121.51 ± 5.98
− 10 µM pargyline 5.83 ± 0.12 120.82 ± 6.73
+ Vehicle 5.31 ± 0.15 145.90 ± 10.40
+ 10 µM pargyline 5.40 ± 0.15 139.47 ± 6.84
− Vehicle 5.66 ± 0.09 105.03 ± 3.57
− 1 mM semicarbazide 5.73 ± 0.08 111.17 ± 5.42
+ Vehicle 5.22 ± 0.11 126.92 ± 8.00
+ 1 mM semicarbazide 5.29 ± 0.09 123.13 ± 6.05
− Vehicle 5.55 ± 0.10 108.83 ± 7.34
− SP 5.61 ± 0.09 110.35 ± 3.20
+ Vehicle 4.73 ± 0.11 121.78 ± 14.43
+ SP 5.13 ± 0.11 125.70 ± 2.56
+ Vehicle 5.36 ± 0.11 132.84 ± 5.90
+ SP 5.41 ± 0.16 142.81 ± 15.39
+ 2000 U/ml catalase 5.10 ± 0.09 113.06 ± 9.12
+ SP + 2000 U/ml catalase 5.68 ± 0.13a 136.49 ± 8.37
− Vehicle 5.72 ± 0.12 116.32 ± 0.57
− 100 µM corticosterone 5.99 ± 0.11 113.98 ± 9.26
+ Vehicle 4.98 ± 0.12 132.78 ± 18.89
+ 100 µM corticosterone 5.14 ± 0.09 107.38 ± 3.39
− Vehicle 5.71 ± 0.10 106.32 ± 3.33
− 1 µM nisoxetine 5.80 ± 0.10 103.55 ± 4.56
+ Vehicle 5.23 ± 0.15 141.99 ± 6.59
+ 1 µM nisoxetine 5.92 ± 0.16* 134.94 ± 10.36
− Vehicle 5.76 ± 0.15 131.05 ± 8.60
− SPC 5.46 ± 0.12 88.31 ± 2.34#
+ Vehicle 5.27 ± 0.13 130.02 ± 6.19
+ SPC 5.41 ± 0.10 108.17 ± 3.63
− Vehicle 5.57 ± 0.11 112.05 ± 6.07
− SPN 5.81 ± 0.11 114.56 ± 3.15
+ Vehicle 4.66 ± 0.10 114.91 ± 3.44
+ SPN 5.86 ± 0.12*** 120.69 ± 6.43
Points represent mean ± SEM for values calculated from figures presented in Figures 8,
9. Unpaired Student’s t-tests were performed to compare −logEC50 values between
tissues with PVAT (+PVAT) and vehicle vs. +PVAT and inhibitor. Maximum contraction
means were compared with a one-way ANOVA and a Holm’s Sidak test for multiple
comparisons. SPC = pargyline (10 µM), and corticosterone (100 µM). SPN =
semicarbazide (1 mM), pargyline (10 µM) and nisoxetine (1 µM). *p < 0.05, ***p < 0.001
vs. +PVAT with vehicle response, #p < 0.05 vs. −/+ PVAT with vehicle, ap < 0.05 vs.
catalase (2000U/ml).
also demonstrated that amine metabolism and NE uptake (which
could assist in providing NE for metabolism intracellularly)
contributes to the protective effect of PVAT.
Optimization of the Western protocol included the use
of antibodies already validated or the validation of the
antibodies. The MAO-A antibody was validated by our
lab for its target specificity (Linder et al., 2008). The
positive control bands on the Western blots for MAO-B were
located by including a competing peptide in a validation
experiment (Data Supplementary Figure 6). AWestern blot was
perform to select an appropriate positive control for COMT
(Data Supplementary Figure 7). A competing peptide for the
COMT antibody used was not commercially available. However,
the Western data was consistent with low expression levels of
mRNA detected. The appropriate band of interest for SSAO was
located on the Western blot after including a competing peptide
in a validation experiment (Data Supplementary Figure 8).
Thus, we have confidence in the band identified by Western blot
for SSAO.
Adipocytes in human abdominal andmammary white adipose
tissue (WAT) contain both MAO-A and MAO-B (Pizzinat et al.,
1999). Expression of mRNA and presence of protein for MAO-
A was found in MPVAT and the MRV. However, expression of
Maob was low in MPVAT. There was higher expression of Aoc3
and SSAO in MPVAT vs. the MRV. SSAO is highly expressed in
adipocytes and has several roles including adipogenesis (Mercier
et al., 2001). In vascular smooth muscle cells, SSAO has roles in
differentiation and the activation of glucose transport (El Hadri
et al., 2002).
Pizzinat et al. (1999) suggested that the uptake-2 system
(OCT3) in adipocytes would take up NE to be inactivated by
MAO. We localized OCT3 to the PVAT adipocyte (Ayala-Lopez
et al., 2015) and identified OCT3 as a mechanism for adipocytes
to take up NE. Inhibition of NET also reduced NE uptake in
MPVAT (Ayala-Lopez et al., 2015). Due to the presence of MAO-
A and SSAO in MPVAT, we could expect metabolism of NE in
PVAT to occur through transport-dependent and independent
processes. If MAO-A is involved in the metabolism of amines
in MPVAT, access to MAO would require an internalization of
the amines from the extracellular environment and OCT3 and/or
NET would be a way that NE can enter cells within MPVAT
to be metabolized. SSAO is present on intracellular membranes
(Enrique-Tarancón et al., 1998) and on the plasma membrane
of adipocytes (Jalkanen and Salmi, 2001) where it is shed in
a process that is regulated by TNF-alpha and insulin (Abella
et al., 2004). Thus, entrance of catecholamines into adipocytes
would not be required for SSAO action. However, inhibition of
SSAO did not affect contraction of arteries to NE. Furthermore,
inhibition of OCT3 and NE metabolism did not significantly
shift the contractility curve but inhibiting NET alone or with SP
shifted the curve of+PVAT arteries. Inactivation of NE by uptake
through NET in MPVAT had the largest effect on contraction.
Stock and Westermann (1963) reported monoamine oxidase
activity in rat epididymal adipose tissue. While, Bour et al. (2007)
reported high MAO-A and SSAO activity in the AF from human
subcutaneous adipose tissue. However, studies in PVAT had
not been performed. We compared the amine oxidase activity
from the MRV and the MPVAT to attain a whole picture of
the oxidase activity in the vascular environment. SSAO was the
predominant oxidase enzyme active in MPVAT. Surprisingly, we
did not detect MAO-A activity in MPVAT although MAO-A
protein and mRNA were present. The high SSAO activity could
have masked lower monoamine oxidase activity and the MAO-A
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FIGURE 9 | NE-induced contraction of mesenteric resistance arteries with and without PVAT incubated with NE uptake inhibitors. (A) NE-induced
contraction of the rat mesenteric resistance arteries + or −PVAT, with corticosterone (100 µM; inhibits OCT3) or vehicle (H2O). (B) NE-induced contraction of the rat
mesenteric resistance arteries + or −PVAT, incubated with nisoxetine (1 µM; inhibits NET) or vehicle (H2O). (C) SPC = semicarbazide (1 mM), pargyline (10 µM), and
corticosterone (100 µM; used to inhibit SSAO, MAO-A/B and OCT3), and (D) SPN = semicarbazide (1 mM), pargyline (10 µM) and nisoxetine (1 µM; used to inhibit
SSAO, MAO-A/B, and NET). The force of contraction was normalized to the percent of the 60 mM KCl contraction. Bars represent means ± SEM. N = the number of
animals used in each group.
activity fell below our level of detection. The inclusion of the
brain and aorta as controls assured us that the assay could detect
and distinguish MAO and SSAO activity.
One limitation is that the substrates used in the oxidase
activity assay, tyramine and benzylamine, are not the likely
endogenous substrates for amine oxidases in PVAT. They were
used as they are well characterized substrates for MAO and
SSAO letting us come to more accurate conclusions as to which
enzymes are active. Candidates for endogenous substrates for
SSAO include aminoacetone, methylamine, 5-HT, and NE Lyles,
1995. Both NE and 5-HT are substrates of SSAO in rat brown
adipose tissue (Barrand and Callingham, 1982). Unfortunately,
NE could not be used in the oxidase assay because of its quick
oxidization by the reagent in the Amplex Red assay (Elliott et al.,
1989b; Zhao et al., 2012). The detection of NE metabolites after
interaction with SSAO could assist in answering the question of
whether NE is a substrate for SSAO in MPVAT. However, we
did not perform these experiments as this assay is still in the
development phase. Observed amine oxidase activities to NE and
other prototypical substrates may be different when compared
across species and adipose depots.
Another possibility is that degradation of amines by oxidation
occurred by other enzymes not tested, especially in the MRV
and the SVF where we were less successful at inhibiting
the oxidase activity with the specific inhibitors used. For
example, ceruloplasmin, an adipokine that is increased in the
adipose tissue of obese humans (Arner et al., 2014), has broad
specificity for degrading amines including NE, epinephrine,
dihydroxyphenylalanine (DOPA), and 5-HT (Gutteridge and
Stocks, 1981).
Due to the closeness of artery and vein in the mesenteric third
order branches and the resulting inability to ascribe PVAT as
belonging to either the artery and vein, both the artery and vein
pair were used in the oxidase assays. The PVAT envelops both
artery and vein, which are positioned close together and without
a clear delineation of PVAT between the two. Thus, to gain an
appreciation of the total tissue amine oxidases within the vascular
environment we have kept the artery and vein together and used
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FIGURE 10 | Diagram of NE handling in PVAT. The hypothesized
mechanism for handling of NE by MPVAT and the MRV is shown above. PVAT
contributes to the uptake and metabolism of NE from the adventitial side of the
artery. Without PVAT, more NE reaches the artery to cause contraction.
all of the PVAT that surrounds them for theWesterns and oxidase
activity assays. In contractility, we have only used the artery since
there is a larger literature base regarding PVAT’s effect on arteries.
However, more studies are needed to understand PVAT’s effect on
veins. Our group is highly interested in the veins of the splanchnic
region and their role in peripheral resistance (Johnson et al., 2002;
Ni et al., 2008; Watts et al., 2015; Seitz et al., 2016). Thus, PVAT’s
effect on veins is an avenue of future research.
Amine metabolism in rat mesenteric arteries has been found
to occur mostly through SSAO, with less involvement from
MAO-A (Elliott et al., 1989a). Elliott et al. (1989c) observed
that inhibiting MAO or SSAO (with clorgyline or MDL 72145,
respectively) did not shift the tyramine response curve of
rat mesenteric arteries (without PVAT). However, a shift was
achieved upon blocking both MAO and SSAO. In our studies,
MAO and SSAO inhibition did not shift the NE-induced
contraction in arteries −PVAT. By contrast, arteries +PVAT
demonstrated a left-shift to NE when MAO, SSAO, and H2O2
were inhibited, supporting a redundant system for inactivating
vasoactive amines that produces H2O2. H2O2 limits endothelial
NO formation and reduces endothelium-dependent relaxation of
the rat aorta (Sturza et al., 2013). In contrast, metabolism of 5-
HT by MAO in the rat basilar artery was shown to lead to H2O2
generation, which by inhibiting the opening of BKCa2+ channels,
potentiated contraction (Poon et al., 2010). Our study supported
that released H2O2 upon NE metabolism was contributing to the
PVAT’s anti-contractile effect.
Our proposed hypothesis is illustrated in Figure 10. On the
left, an artery with PVAT is exposed to NE. The NE is taken up
throughNET and subsequently is metabolized in the PVAT either
through SSAO orMAO. A small amount of NE reaches the artery
relative to the amount of NE originally released along with H2O2
and less contraction of the artery occurs. On the right, an artery
with the PVAT removed is exposed to NE. The full amount of NE
reaches the artery to cause contraction. A small amount of NE
(not enough to affect contraction) may be metabolized within the
artery.
We can place our findings in context of the disease that
brought us to examine aminemetabolism in PVAT. SSAO activity
in MPVAT could influence vascular inflammation as it has a
role in inflammation and is being explored as a biomarker for
atherosclerosis (Mészáros et al., 1999; Karadi et al., 2002). In
obesity, SSAO and MAO activity near the vessel could promote
vascular remodeling. We do not have data to support this. Thus,
investigation into SSAO and MAO activity in PVAT during
obesity in necessary.
CONCLUSIONS
The MRV and MPVAT with its corresponding AF and SVF
contain amine oxidase activity mostly attributed to SSAO. Amine
metabolism and NE uptake in PVAT protects arteries from
contraction to NE. Studies are necessary to understand how this
NE handling system functions in human PVAT and how it may
be altered in obesity.
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Data Supplementary Figure 1 | Image representing the rat mesenteric
vessels and PVAT used in this study. The location of the mesenteric resistance
artery-vein pair used is indicated by the red arrow and their associated MPVAT is
indicated by the white arrow.
Data Supplementary Figure 2 | Image representing the AF and the SVF
isolated from whole MPVAT. Representative of the following experiments where
the AF (left) and SVF (right) were used. Phase contrast images were taken with a
20× objective. The black scale bar = 100 µM.
Data Supplementary Figure 3 | Comparison of the force of contraction
between the +PVAT and −PVAT mesenteric resistance arteries. Arteries
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were exposed to 60 mM KCl at the beginning of each experiment. Graphed are
the “initial” force of contraction of the arteries + and −PVAT from the experiments
shown in Figures 8, 9. Data were compared with a paired t-test and shown to be
non-significant (p = 0.20). Bars represent means ± SEM. N, the number of
animals used in each group. NS, non-significant (p > 0.05).
Data Supplementary Figure 4 | Comparison of the force of contraction
between the +PVAT and −PVAT mesenteric resistance arteries at the
initial part of the experiment vs. the end of experiment. Arteries were
exposed to 60 mM KCl at the beginning of each experiment and at the end.
Graphed are the “initial” vs. the “end” forces of contraction of the arteries + and
−PVAT from Figure 8. Data were compared with a 2-way ANOVA and shown to
be non-significant. Bars represent means ± SEM. N, the number of animals used
in each group.
Data Supplementary Figure 5 | Comparison of the force of contraction
between the +PVAT and −PVAT mesenteric resistance arteries at the
initial part of the experiment vs. the end of experiment. Arteries were
exposed to 60 mM KCl at the beginning of each experiment and at the end.
Graphed are the “initial” vs. the “end” forces of contraction of the arteries + and
−PVAT from Figure 9. Data were compared with a 2-way ANOVA. Bars represent
means ± SEM. N, the number of animals used in each group. ∗p < 0.05.
Data Supplementary Figure 6 | MAO-B Western blot optimization
experiment. Western blots for MAO-B were prepared that were exposed to
anti-MAO-B antibody (no peptide; left) or the antibody and the competing
peptide (right) to locate the band for MAO-B and select the appropriate
positive control tissue. MAO-B signal was observed at around 45 kDa. The
stomach fundus gave the least non-specific signal and thus was selected as
the positive control.
Data Supplementary Figure 7 | COMT Western blot optimization
experiment. Western blots for COMT were prepared to select the proper
positive control tissue. COMT signal was observed at around 45 kDa. The
competing peptide was not commercially available. The Jurkat whole cell
lysate gave the least non-specific signal and thus was selected as the positive
control.
Data Supplementary Figure 8 | VAP-1 (SSAO) Western blot optimization
experiment. Western blots for VAP-1 (SSAO) were prepared that were exposed
to anti-VAP-1 antibody (no peptide; left) or the antibody and the competing
peptide (right) to locate the band for VAP-1. VAP-1 signal was observed at around
80 kDa. The lung was the positive control in this experiment. However, because
the signal was not strong, the aorta was used as the positive control in
subsequent experiments.
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